Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Multimerin-1 (MMRN1) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group.

Tytuł:
Multimerin-1 (MMRN1) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group.
Autorzy:
Laszlo GS; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Alonzo TA; Department of Biostatistics, University of Southern California, Los Angeles, California. Children's Oncology Group, Monrovia, California.
Gudgeon CJ; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Harrington KH; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Gerbing RB; Children's Oncology Group, Monrovia, California.
Wang YC; Children's Oncology Group, Monrovia, California.
Ries RE; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Raimondi SC; Children's Oncology Group, Monrovia, California. Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Hirsch BA; Children's Oncology Group, Monrovia, California. Department of Laboratory Medicine and Pathology, University of Minnesota Cancer Center, Minneapolis, Minnesota.
Gamis AS; Children's Oncology Group, Monrovia, California. Division of Hematology-Oncology, Children's Mercy Hospitals and Clinics, Kansas City, Missouri.
Meshinchi S; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. Children's Oncology Group, Monrovia, California. Department of Pediatrics, University of Washington, Seattle, Washington.
Walter RB; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. Division of Hematology, Department of Medicine, University of Washington, Seattle, Washington. Department of Epidemiology, University of Washington, Seattle, Washington. .
Źródło:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2015 Jul 15; Vol. 21 (14), pp. 3187-95. Date of Electronic Publication: 2015 Mar 30.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Original Publication: Denville, NJ : The Association, c1995-
MeSH Terms:
Biomarkers, Tumor/*analysis
Blood Proteins/*biosynthesis
Leukemia, Myeloid, Acute/*pathology
Adolescent ; Blood Proteins/analysis ; Child ; Child, Preschool ; Clinical Trials, Phase III as Topic ; Disease-Free Survival ; Female ; Flow Cytometry ; Humans ; Infant ; Kaplan-Meier Estimate ; Leukemia, Myeloid, Acute/mortality ; Male ; Multicenter Studies as Topic ; Prognosis ; Proportional Hazards Models ; Retrospective Studies ; Reverse Transcriptase Polymerase Chain Reaction ; Young Adult
References:
Cancer. 2012 Feb 1;118(3):761-9. (PMID: 21766293)
J Biol Chem. 2012 Mar 30;287(14):11498-515. (PMID: 22334695)
Blood. 2007 Aug 15;110(4):1238-50. (PMID: 17420287)
Front Immunol. 2012 Jan 06;2:93. (PMID: 22566882)
Methods. 2001 Dec;25(4):402-8. (PMID: 11846609)
Blood Rev. 2006 Nov;20(6):333-42. (PMID: 16920238)
Platelets. 2008 Mar;19(2):83-95. (PMID: 18297547)
Nat Protoc. 2008;3(6):1101-8. (PMID: 18546601)
Blood. 2012 Aug 23;120(8):1581-8. (PMID: 22649108)
JAMA. 2010 Dec 22;304(24):2706-15. (PMID: 21177505)
Leuk Lymphoma. 2014 Dec;55(12):2817-21. (PMID: 24559289)
Blood. 2010 Jan 21;115(3):453-74. (PMID: 19880497)
J Biol Chem. 2013 Apr 12;288(15):10628-39. (PMID: 23463512)
PLoS One. 2012;7(7):e40321. (PMID: 22815738)
Blood. 1991 Jun 15;77(12):2556-60. (PMID: 2043761)
J Clin Oncol. 2014 Sep 20;32(27):3021-32. (PMID: 25092781)
J Clin Oncol. 2010 Jun 10;28(17):2831-8. (PMID: 20421533)
Blood. 1998 Nov 1;92(9):3115-22. (PMID: 9787146)
J Biol Chem. 1991 Apr 15;266(11):7114-20. (PMID: 2016319)
Thromb Haemost. 2005 Nov;94(5):1004-11. (PMID: 16363244)
Blood. 2009 Jun 25;113(26):6558-66. (PMID: 19304957)
Blood. 2009 Jan 22;113(4):866-74. (PMID: 18927435)
Grant Information:
U10-CA180899 United States CA NCI NIH HHS; P30-CA015704-35S6 United States CA NCI NIH HHS; P30 CA015704 United States CA NCI NIH HHS; U24-CA114766 United States CA NCI NIH HHS; U24 CA114766 United States CA NCI NIH HHS; U10-CA098543 United States CA NCI NIH HHS; R21 CA161894 United States CA NCI NIH HHS; U10 CA098543 United States CA NCI NIH HHS; S10 OD020069 United States OD NIH HHS; U10 CA180899 United States CA NCI NIH HHS; U10 CA180886 United States CA NCI NIH HHS; R21-CA161894 United States CA NCI NIH HHS
Substance Nomenclature:
0 (Biomarkers, Tumor)
0 (Blood Proteins)
0 (multimerin)
Entry Date(s):
Date Created: 20150401 Date Completed: 20160510 Latest Revision: 20181113
Update Code:
20240104
PubMed Central ID:
PMC4506237
DOI:
10.1158/1078-0432.CCR-14-2684
PMID:
25825478
Czasopismo naukowe
Purpose: Exploratory gene expression array analyses suggested multimerin-1 (MMRN1) to be a predictive biomarker in acute myelogenous leukemia (AML). Following up on these studies, we evaluated the role of MMRN1 expression as outcome predictor in two recent Children's Oncology Group trials.
Experimental Design: We retrospectively quantified MMRN1 expression in 183 participants of AAML03P1 and 750 participants of AAML0531 by reverse-transcriptase PCR and correlated expression levels with disease characteristics and clinical outcome.
Results: In AAML03P1, the highest quartile of MMRN1 expression (expression ≥0.5 relative to β-glucuronidase; n = 45) was associated with inferior event-free survival (EFS; P < 0.002) and higher relapse risk (P < 0.004). In AAML0531, in which we quantified MMRN1 mRNA for validation, patients with relative MMRN1 expression ≥0.5 (n = 160) less likely achieved remission (67% vs. 77%, P = 0.006), and more frequently had minimal residual disease (43% vs. 24%, P = 0.001) after one induction course. They had inferior overall survival (OS; 44% ± 9% vs. 69% ± 4% at 5 years; P < 0.001) and EFS (32% ± 8% vs. 54% ± 4% at 5 years; P < 0.001) and higher relapse risk (57% ± 10% vs. 35% ± 5% at 5 years; P < 0.001). These differences were partly attributable to the fact that patients with high MMRN1 expression less likely had cytogenetic/molecular low-risk disease (P < 0.001) than those with low MMRN1 expression. Nevertheless, after multivariable adjustment, high MMRN1 expression remained statistically significantly associated with shorter OS (HR, 1.57; 95% confidence interval, 1.17-2.12; P = 0.003) and EFS (HR, 1.34; 1.04-1.73; P = 0.025), and higher relapse risk (HR, 1.40; 1.01-1.94; P = 0.044).
Conclusions: Together, our studies identify MMRN1 expression as a novel biomarker that may refine AML risk stratification.
(©2015 American Association for Cancer Research.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies